Company intelligence / Profile preview

Thermosome

Planegg/Martinsried, Bavaria, Germanythermosome.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Initial clinical data from the ongoing Phase I trial of THE001 show encouraging safety and early signs of efficacy. No renal or cardiac impairment or formulation-related adverse events were observed; no patients discontinued due to adverse events. The approach achieves up to a 15-fold increase in local tumor drug concentration with a favorable pharmacokinetic profile compared to conventional doxorubicin.[2] The company has initiated the final dose level in its Phase I trial as of early 2024.[1] European Orphan Drug Designation granted for STS.[5]

Therapeutic areas: Oncology
Modalities: Thermosensitive liposomal drug delivery (TSL)Small molecules (doxorubicin)
Industry: Biotech

Drug pipeline

2 assets

TSL-DOX

1 more asset in the full pipeline.

Partnerships

IMAGIO Consortium participation to improve cancer treatment

Beyond the preview

Go deeper on Thermosome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thermosome.